Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

OMF Newsletter – Winter 2018


2018 Begins with a Special $5 Million Gift from the Pineapple Fund

Early in January, we were joyfully surprised by a generous $1 million gift from the Pineapple Fund, an anonymous bitcoin investor whose website states “because once you have enough money, money doesn’t matter.”

“Pine” said that he/she is “inspired and excited by the work” that OMF is doing and understands how devastating this illness can be. Pine said that “this is one of the most important research areas that Pineapple Fund can fund.”

We are overjoyed that, less than two weeks after announcing this gift, “Pine” committed to donating another $4 million to OMF.

We invite you to join us in thanking the Pineapple Fund by adding your appreciation to our online community-wide thank you card. Click here to add your message: Community Thank You Card


Thank you for Making 2017 a Remarkable Year!

We are thrilled to share that with your generous support we raised over $3 million in 2017 to accelerate our urgent research agenda!

Thank you to each and every person who donated from $1 to $1 million. As a united community, we are advancing research that will find answers to end ME / CFS.

In the coming weeks, we will share with you a detailed summary of the many accomplishments you helped OMF make in 2017. Watch your inbox!

 


Introducing the New Analyzing Patient Data Study (APS)

We are launching this new research study to perform a retrospective analysis of clinical laboratory data from hundreds of ME / CFS patients. This study will gather and analyze the clinical laboratory tests and results ordered by ME / CFS specialists. We are hopeful that analyzing a large number of clinical records using robust statistical methods may reveal new insights.

Drs. David Kaufman and Bela Chheda (Center for Complex Diseases, CA) and Dr. Susan Levine (ME / CFS Clinician & Researcher, NY) will lead the first phase of this study using de-identified results from their patients. Later, we hope to bring on additional clinicians. Eventually, we plan to share the results with the whole ME / CFS medical and research communities.

We are very grateful to our newest partner, Statisticians without Borders, who has stepped in to lead the data analysis pro-bono. We are grateful to Hany Zayed, PhD, Head of Data Sciences Solutions, Rigel Pharmaceuticals and Statisticians Without Borders volunteer who will lead this project.


Update: Metabolomics Validation Study

Dr. Robert Naviaux has shared a preliminary summary of the results of the OMF funded Metabolomics Validation Study, which aims to validate his groundbreaking findings of metabolic features of ME / CFS that he published in 2016. Dr. Naviaux reports:

“23 of 30 (77%) of the pathway abnormalities in males and females that were found in the ME / CFS1 study were validated in the ME / CFS2 study, despite large differences in clinical practice, and geography between the two patient cohorts.

Overall, these results add support for the conclusions of the ME / CFS1 study. The syndrome of ME / CFS results from the persistence of a dauer-like metabolic program that produces an energy conservation state mediated by a persistent cell danger response (CDR) to harsh environmental conditions, but at the cost of long-term disability.”

We will continue to keep you updated on this study.


Update on Suramin Clinical Trials

Dr. Robert Naviaux has informed us that, “Bayer has made the decision not to provide suramin for his proposed clinical trials in autism and ME / CFS. A new, FDA-approved source of suramin is expected to become available in about a year.” Dr. Naviaux plans to begin his FDA-approved studies in autism and ME / CFS when the new suramin becomes available.

Dr. Naviaux continues, “While this news is disappointing, there are some advantages to waiting for this new suramin manufacturer.” In the past, Bayer has been slow to take interest in new projects, which has led to interruptions in Dr. Naviaux’s studies.

“We are hopeful that the new supplier of suramin will, in the long run, offer a simpler path forward and fewer potential delays in testing. If future clinical trials show that suramin is safe and effective in treating ME / CFS, then the FDA will have all they need to make a decision on approval in a shorter period of time than before. Ultimately, this means that the drug can become available for patients with ME / CFS faster than was possible before,” said Dr. Naviaux.

We will continue to keep you updated about the new manufacturer.


A Word from our CEO/President

As we begin the new year, we are filled with hope, optimism, and a renewed commitment to accelerating research. Each and every day the patient community is in our minds and hearts and inspiring us to do more and work faster.

OMF is working on many projects to help improve the lives of all patients. In the coming months, you will be learning about many of these new and expanded efforts. Thank you for your ongoing support to help establish and advance this important work.

One of our major goals is keeping you, our community, informed. If at any time you miss our news in your inbox, please be certain to check our website for the latest newsletters and news.  In addition, if you are not on Facebook, please be certain to check our website weekly for the latest Science Wednesday posts.

Working together, I am looking forward to 2018 as a year of great hope and promise.

With hope for all,


Linda Tannenbaum
CEO/President
Linda@omf.ngo

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo